If you are considering the GeneSight pharmacogenomic test to guide your mental health treatment, the decision is no longer just about the science; it is about navigating a complex 2026 landscape of ...

Dylan Eyestone submits a cheek swab as part of the GeneSight test he took through his mental healthcare provider, Dawn Johnson. The sample is analyzed in a lab and Johnson receives a report detailing ...

The combinatorial, multi-gene GeneSight test has been found to better predict antidepressant treatment outcomes for patients with depression, and their use of health care resources, than any of the ...

Myriad Genetics, Inc. MYGN recently announced improvements to the GeneSight Psychotropic test, a pharmacogenomic test for drugs used to treat mental illness. The GeneSight report will now contain ...

SALT LAKE CITY, April 30, 2026 (GLOBE NEWSWIRE) -- The latest GeneSight ® Mental Health Monitor, a nationwide survey from Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic ...

SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of Clinical ...

Myriad Genetics, Inc. announced that a study published in the Journal of Clinical Psychopharmacology found that the GeneSight® Psychotropic Test significantly reduced psychiatric hospitalizations in ...

An astonishing 44% of Americans feel they have lost time in their lives due to poor mental health. That number jumps to nearly 80% for those diagnosed with anxiety and/or depression, according to the ...